NCT02735239 - Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 24, 2016

Primary Completion Date

June 16, 2022

Study Completion Date

June 16, 2022

Conditions

Esophageal Cancer

Interventions

DRUG

Durvalumab

Anti PD-L1 antibody

DRUG

Tremelimumab

Anti CTLA-4 antibody

DRUG

Oxaliplatin

IV administered chemotherapy

DRUG

Capecitabine

orally-administered chemotherapy

RADIATION

Radiotherapy

DRUG

Paclitaxel

IV administered chemotherapy

DRUG

Carboplatin

IV administered Chemotherapy

DRUG

5-fluorouracil (5-FU)

IV administered chemotherapy

DRUG

Leucovorin

chemo-protective agent

DRUG

Docetaxel

IV administered chemotherapy

Trial Locations (4)

DD1 9SY

Research Facility, Dundee

NG5 1PB

Research Facility, Nottingham

OX3 9DU

Research Facility, Oxford

SO16 6YD

Research Facility, Southampton